Change in biomarkers of serum after supplementation of vitamin D in breast cancer patients
Biomarkers | Placebo | Vitamin D | Absolute treatment effecta | ||||||
---|---|---|---|---|---|---|---|---|---|
Baseline | 2 Months | Pc | Baseline | 2 Months | Pc | Placebo | Vitamin D | Pb | |
25(OH)D (ng/mL) | 15.3 ± 2.2 | 13.4 ± 2.2 | 0.59 | 28 ± 2.6 | 39 ± 3.5 | 0.004* | –1.9 ± 0.9 | 11 ± 3.1 | 0.001* |
TNF-α (pg/mL) | 32.6 ± 8 | 25.6 ± 3.2 | 0.19 | 13.4 ± 1.1 | 14.5 ± 1.6 | 0.96 | 7 ± 2.1 | 1.1 ± 2.1 | 0.18 |
TGF-β (pg/mL) | 123.4 ± 9 | 133.8 ± 10 | 0.24 | 293.8 ± 48.8 | 288 ± 42.9 | 0.84 | 10.4 ± 7.1 | –5.6 ± 33.4 | 0.64 |
TAC (U/mL) | 45.2 ± 11.5 | 29.2 ± 8.3 | 0.001* | 48.9 ± 13.3 | 63.5 ± 13.3 | 0.004* | –16 ± 8.4 | 14.6 ± 8.9 | 0.017* |
a Absolute treatment effect is the absolute change from baseline to follow-up in the treatment group minus the absolute change from baseline to follow-up in the placebo group; b P values for differences between the treatment and placebo groups; c P values for difference between baseline visit and post-intervention values; * P value < 0.05; values are mean ± SD